- Review
Gliomas remain refractory to contemporary neurosurgical and adjuvant therapies due to diffuse infiltration, immune evasion, and rapid development of therapeutic resistance. Extracellular vesicles (EVs), lipid-encapsulated substrates of various sizes that carry nucleic acid or proteins, are now recognized as central regulators of tumor–immune crosstalk and a potential unifying mechanism linking microenvironmental reprogramming with disease progression. Glioma-derived EVs function as active signaling platforms that remodel the tumor microenvironment. EV cargo—including PD-L1, TGF-β, and regulatory microRNAs—suppresses cytotoxic T-cell function, promotes M2 macrophage polarization, and impairs dendritic cell antigen presentation, collectively reinforcing an immunosuppressive niche. Additionally, EV-mediated transfer of resistance-associated cargo contributes to chemoresistance and radioresistance, representing key paracrine mechanisms of treatment failure. EV-associated nucleic acids specifically have enabled detection of alterations such as EGFRvIII, IDH1 mutations, and MGMT promoter methylation in early clinical studies. These findings support EV-based liquid biopsy as a promising approach for minimally invasive molecular characterization and disease monitoring. However, most mechanistic and therapeutic evidence remains preclinical, while clinical studies are limited by small cohorts, heterogeneous EV isolation and characterization methods, and a lack of prospective validation. Ultimately, EVs represent a biologically important interface between glioma biology and the immune microenvironment, with emerging applications in disease monitoring and therapeutic development. Prospective validation and technical standardization remain essential to enable clinical translation.
13 November 2026







![Evidence-graded framework for sEV-associated brain–body communication in mood disorders. (A) Candidate CNS cellular sources, marker-enriched sEV fractions measured in peripheral blood, and hypothesised peripheral target systems. Cellular origin is inferred from enrichment markers and is not directly established. Human associative findings are shown for astrocyte-marker-enriched, microglia-marker-enriched, and neuron-marker-enriched sEV fractions. (B) Experimental evidence from mood-disorder transfer studies in rodent models [36,59,81], in which patient-associated EVs produced brain-directed functional effects, while peripheral target organs were not examined. (C) Proof of principle outside mood disorders [24], demonstrating astrocyte-to-liver signalling in an acute inflammatory rodent model. Legend: solid-bordered sEV fraction boxes indicate human associations in mood disorders; grey dashed arrows indicate putative cellular origin inferred from marker-based enrichment; solid black arrows indicate experimentally demonstrated transfer or functional effects in rodent models; and purple dashed arrows indicate hypothesised pathways not demonstrated in mood disorders; downward arrows indicate decreased expression; upward arrows indicate increased expression. CNS, central nervous system; sEV, small extracellular vesicle; BDNF, brain-derived neurotrophic factor; VEGF, vascular endothelial growth factor; ECT, electroconvulsive therapy; VDBP, vitamin D-binding protein; and TNFR1, tumour necrosis factor receptor 1.](https://mdpi-res.com/neuroglia/neuroglia-07-00035/article_deploy/html/images/neuroglia-07-00035-g001-550.jpg)
